Navoximod (BioDeep_00000802600)
代谢物信息卡片
化学式: C18H21FN2O2 (316.1587)
中文名称: 那伏莫德
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(CCC1C(CC2C3=C(C=CC=C3F)C4=CN=CN24)O)O
InChI: InChI=1S/C18H21FN2O2/c19-14-3-1-2-13-16-9-20-10-21(16)15(18(13)14)8-17(23)11-4-6-12(22)7-5-11/h1-3,9-12,15,17,22-23H,4-8H2/t11?,12?,15-,17+/m0/s1
描述信息
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent
C308 - Immunotherapeutic Agent > C141144 - Immune Checkpoint Modulator
C471 - Enzyme Inhibitor > C141137 - IDO1 Inhibitor
C274 - Antineoplastic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D11255
- PubChem: 70914230
- DrugBank: DB15439
- ChEMBL: CHEMBL4530496
- ChEMBL: CHEMBL3989951
- CAS: 1402837-78-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
亚细胞结构定位 | 关联基因列表 |
---|
文献列表
- Cui Huo, Zongyuan Luo, Xiangli Ning, Xin Kang, Qin Yan, Yuying Guo, Guobo Li, Zhouyu Wang, Yuzhi Li, Shan Qian. 4,6-Disubstituted-1H-Indazole-4-Amine derivatives with immune-chemotherapy effect and in vivo antitumor activity.
European journal of medicinal chemistry.
2022 Nov; 241(?):114625. doi:
10.1016/j.ejmech.2022.114625
. [PMID: 35952399] - Xiang-Li Ning, Yu-Zhi Li, Cui Huo, Ji Deng, Cheng Gao, Kai-Rong Zhu, Miao Wang, Yu-Xiang Wu, Jun-Lin Yu, Ya-Li Ren, Zong-Yuan Luo, Gen Li, Yang Chen, Si-Yao Wang, Cheng Peng, Ling-Ling Yang, Zhou-Yu Wang, Yong Wu, Shan Qian, Guo-Bo Li. X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Journal of medicinal chemistry.
2021 06; 64(12):8303-8332. doi:
10.1021/acs.jmedchem.1c00303
. [PMID: 34110158] - Shuguang Ma, Julia Suchomel, Evelyn Yanez, Edward Yost, Xiaorong Liang, Rui Zhu, Hoa Le, Nicholas Siebers, Lori Joas, Roland Morley, Stephanie Royer-Joo, Andrea Pirzkall, Laurent Salphati, Joseph A Ware, Kari M Morrissey. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
British journal of clinical pharmacology.
2019 08; 85(8):1751-1760. doi:
10.1111/bcp.13961
. [PMID: 30973970] - Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F Stephen Hodi, Myung-Ju Ahn, Leisha A Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S Lindsey Davis. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019 06; 25(11):3220-3228. doi:
10.1158/1078-0432.ccr-18-2740
. [PMID: 30770348]